Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz

Morning Hubsters,

Happy Fri-yay! John R Fischer here, coming to you from the New York newsroom with the US Wire.

Wellness and preventative health trends are making nutraceuticals popular among consumers. This demand is attracting private equity firms, such as Butterfly Equity, Graham Partners and Wise Equity. We’ll discuss a few deals by these firms in my seven-deal listicle.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *